Boston Trust Walden Corp Sells 128,927 Shares of Core Laboratories Inc. (NYSE:CLB)

Boston Trust Walden Corp lessened its stake in Core Laboratories Inc. (NYSE:CLB) by 17.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 600,833 shares of the oil and gas company’s stock after selling 128,927 shares during the quarter. Boston Trust Walden Corp owned approximately 1.28% of Core Laboratories worth $11,133,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of CLB. Louisiana State Employees Retirement System increased its position in Core Laboratories by 2.2% in the second quarter. Louisiana State Employees Retirement System now owns 23,600 shares of the oil and gas company’s stock worth $479,000 after buying an additional 500 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Core Laboratories by 3.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,054 shares of the oil and gas company’s stock worth $366,000 after acquiring an additional 579 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in Core Laboratories by 11.9% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 5,636 shares of the oil and gas company’s stock worth $114,000 after acquiring an additional 600 shares during the last quarter. Oppenheimer Asset Management Inc. raised its stake in Core Laboratories by 1.4% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 54,310 shares of the oil and gas company’s stock valued at $1,102,000 after acquiring an additional 758 shares during the period. Finally, Signaturefd LLC lifted its holdings in Core Laboratories by 12.8% during the second quarter. Signaturefd LLC now owns 6,776 shares of the oil and gas company’s stock valued at $137,000 after purchasing an additional 767 shares during the last quarter. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CLB shares. Piper Sandler reduced their target price on shares of Core Laboratories from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Monday, July 15th. StockNews.com lowered shares of Core Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, September 17th. Bank of America dropped their target price on Core Laboratories from $16.00 to $15.00 and set an “underperform” rating on the stock in a research report on Monday, July 15th. Finally, Stifel Nicolaus lifted their price target on Core Laboratories from $18.00 to $22.00 and gave the company a “hold” rating in a research report on Friday, July 26th. Two analysts have rated the stock with a sell rating and two have given a hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $18.00.

Core Laboratories Price Performance

CLB stock opened at $19.43 on Friday. The firm has a 50 day moving average of $18.53 and a 200-day moving average of $18.98. The firm has a market capitalization of $911.27 million, a P/E ratio of 22.08, a price-to-earnings-growth ratio of 1.08 and a beta of 2.36. Core Laboratories Inc. has a 12 month low of $13.82 and a 12 month high of $25.13. The company has a current ratio of 2.39, a quick ratio of 1.68 and a debt-to-equity ratio of 0.60.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings results on Wednesday, October 23rd. The oil and gas company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.21 by $0.04. The firm had revenue of $134.40 million during the quarter, compared to the consensus estimate of $134.16 million. Core Laboratories had a net margin of 5.44% and a return on equity of 15.20%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same period last year, the firm earned $0.22 EPS. As a group, sell-side analysts predict that Core Laboratories Inc. will post 0.8 earnings per share for the current fiscal year.

Core Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 25th. Shareholders of record on Monday, November 4th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Monday, November 4th. This represents a $0.04 dividend on an annualized basis and a yield of 0.21%. Core Laboratories’s dividend payout ratio is currently 4.55%.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.